Publications by authors named "C Erol"
Article Synopsis
- The study compared the effectiveness and safety of FOLFIRI combined with bevacizumab versus FOLFIRI combined with aflibercept in patients with RAS-mutant metastatic colon cancer who had previously received treatment.
- Results showed that patients receiving FOLFIRI with bevacizumab had a median overall survival (OS) of 14.1 months and progression-free survival (PFS) of 7.7 months, which were significantly better than those treated with aflibercept (OS: 11.2 months, PFS: 5.7 months).
- Additionally, the bevacizumab group experienced fewer severe side effects (50.9% in aflibercept group vs 25.
Background And Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed HCC in this unique setting. This study aimed to assess the efficacy of Sorafenib and Regorafenib in patients with HCC who experienced recurrence after liver transplantation.
View Article and Find Full Text PDFTwins with Hypertrophic Cardiomyopathy, circRNAs in Viral Myocarditis….
Anatol J Cardiol
November 2024